The Use of Checkpoint Inhibitors in Classical Hodgkin’s Lymphoma during the COVID-19 Pandemic (Pirogov Medical Center’s Experience)

Vladislav Olegovich Sarzhevskii, E.A. Demina, N.E. Mochkin, A.A. Spornik, A.A. Mamedova, E.G. Smirnova, A.E. Bannikova, A.A. Samoilova, V.S. Bogatyrev, O.Yu. Bronov, Yu.A. Abovich, V.Ya. Melnichenko,

DOI:

https://doi.org/10.21320/2500-2139-2020-13-3-307-315

Background. Currently, there are neither systematic data nor clinical guidelines for checkpoint inhibitor immunotherapy in cancer patients in the context of the COVID-19 pandemic. In this respect classical Hodgkin’s lymphoma (cHL) is no exception. The article deals with the experience of Pirogov Medical Center (NI Pirogov Russian National Medical Center of Surgery) in PD-1-inhibitor immunotherapy in relapsed/refractory cHL in the context of the COVID-19 pandemic. The authors endeavour to cover matters of current interest concerning immunotherapy and differential diagnosis of pulmonary adverse events emerging in the context of new realities in providing medical care to cancer patients.

Aim. To assess feasibility and safety of checkpoint inhibitor immunotherapy in relapsed/refractory cHL in the context of the COVID-19 pandemic.

Materials & Methods. This is a retrospective analysis of adverse events of therapy and COVID-19 mortality, and incidence in 50 cHL patients who received immunotherapy at the Pirogov Medical Center in the period of spring COVID-19 pandemic in 2020.

Results. During the reported period (from March 11, 2020, when the COVID-19 pandemic was declared, to May 25, 2020) the group of 50 cHL patients showed relatively low overall incidence rate of newly diagnosed immune-mediated adverse events (14 %; n = 7). Severe adverse events were identified in 2 (4 %) patients. Bacterial infection incidence was 6 % (n = 3). Clinical signs of corona virus confirmed by subsequent laboratory COVID-19 tests were observed in 2 (4 %) patients. One patient died due to the non-COVID-19-associated reason. The main issue the center’s staff was faced with was the need for differential diagnosis between drug-induced (as well as immune-mediated) pulmonitis and COVID-19-associated pneumonia.

Conclusion. The retrospective analysis reveals that PD-1-inhibitor immunotherapy in cHL patients during the COVID-19 pandemic is a feasible method of therapy, but it requires high awareness. Special focus should be given to clinical and radiological similarities of COVID-19-associated pneumonia and pulmonitis as a complication of immunotherapy.

  • Vladislav Olegovich Sarzhevskii NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • E.A. Demina NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • N.E. Mochkin NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • A.A. Spornik NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • A.A. Mamedova NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • E.G. Smirnova NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • A.E. Bannikova NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • A.A. Samoilova NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • V.S. Bogatyrev NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • O.Yu. Bronov NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • Yu.A. Abovich NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  • V.Ya. Melnichenko NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203 ; ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203
  1. Coronavirus W.H.O. WHO; 2020. COVID-19. [Internet] Available from: https://who.sprinklr.com. (accessed 28.05.2020).
  2. Стопкороновирус.рф. [электронный документ] Доступно по: https://стопкоронавирус.рф. Ссылка активна на 28.05.2020.[Stopcoronavirus.rf. [Internet] Available from: https://стопкоронавирус.рф (accessed 28.05.2020) (In Russ)]
  3. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7. doi: 10.1016/S1470-2045(20)30096-6. DOI: https://doi.org/10.1016/S1470-2045(20)30096-6
  4. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2000 (in press). doi: 10.1016/j.annonc.2020.03.296. DOI: https://doi.org/10.1016/j.annonc.2020.03.296
  5. Petrelli F, Ardito R, Borgonovo K, et al. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2018;103:7–16. doi: 10.1016/j.ejca.2018.07.129. DOI: https://doi.org/10.1016/j.ejca.2018.07.129
  6. Finkel I, Sternschuss M, Wollner M, et al. Immune-related neutropenia following treatment with immune checkpoint inhibitors. J Immunother. 2020;43(2):67–74. doi: 10.1097/CJI.0000000000000293. DOI: https://doi.org/10.1097/CJI.0000000000000293
  7. Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020;20(1):e9. doi: 10.4110/in.2020.20.e9. DOI: https://doi.org/10.4110/in.2020.20.e9
  8. Stroud CR, Hegde A, Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25(3):551–7. doi: 10.1177/1078155217745144. DOI: https://doi.org/10.1177/1078155217745144
  9. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Nat Acad Sci. 2020;117(20):10970–5. doi: 10.1073/pnas.2005615117. DOI: https://doi.org/10.1073/pnas.2005615117
  10. Ansell S, Lesokhin A, Borrello I, et al. PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. N Engl J Med. 2015;372(4):311–9. doi: 10.1056/NEJMoa1411087. DOI: https://doi.org/10.1056/NEJMoa1411087
  11. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428–39. doi: 10.1200/JCO.2017.76.0793. DOI: https://doi.org/10.1200/JCO.2017.76.0793
  12. Chen R, Zinzani P, Fanale M, et al. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017;35(19):2125–32. doi: 10.1200/JCO.2016.72.1316. DOI: https://doi.org/10.1200/JCO.2016.72.1316
  13. D’Souza A, Jaiyesimi I, Trainor L, et al. Granulocyte Colony-Stimulating Factor Administration: Adverse Events. Transfus Med Rev. 2008;22(4):280–90. doi: 10.1016/j.tmrv.2008.05.005. DOI: https://doi.org/10.1016/j.tmrv.2008.05.005
  14. Rochefoucauld J, Noel N, Lambotte O. Management of Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Cancer Patients: A Patient-Centred Approach. Intern Emerg Med. 2020. doi: 10.1007/s11739-020-02295-2. DOI: https://doi.org/10.1007/s11739-020-02295-2
  15. Diamantopoulos P, Gaggadi M, Kassi E, et al. Late-onset Nivolumab-Mediated Pneumonitis in a Patient With Melanoma and Multiple Immune-Related Adverse Events. Melanoma Res. 2017;27(4):391–5. doi: 10.1097/CMR.0000000000000355. DOI: https://doi.org/10.1097/CMR.0000000000000355

Keywords:

classical Hodgkin’s lymphoma, immunotherapy, PD-1-inhibitors, COVID-19 pandemic

License

Copyright (c) 2020 Clinical Oncohematology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.

For Contact

  • Vladislav Olegovich Sarzhevskii, MD, PhD, NI Pirogov Russian National Medical Center of Surgery, 70 Nizhnyaya Pervomaiskaya str., Moscow, Russian Federation, 105203, ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава России, ул. Нижняя Первомайская, д. 70, Москва, Российская Федерация, 105203, e-mail: vladsar100@gmail.com
2020-3

Downloads

Published

01.07.2020

Issue

Vol. 13 No. 3 (2020)
LYMPHOID TUMORS

How to Cite

Sarzhevskii V.O., Demina E.D., Mochkin N.E., et al. The Use of Checkpoint Inhibitors in Classical Hodgkin’s Lymphoma during the COVID-19 Pandemic (Pirogov Medical Center’s Experience). Clinical Oncohematology. Basic Research and Clinical Practice. 2020;13(3):307–315. doi:10.21320/2500-2139-2020-13-3-307-315.

Most read articles by the same author(s)

1 2 > >>